• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland
ConclusionsAll DOACs were similarly effective in preventing strokes and systemic embolisms, while patients being treated with rivaroxaban exhibited the highest bleeding risks. Observed differences in the risks of all ‐cause mortality, myocardial infarction, and pulmonary embolism warrant further research.
Source: British Journal of Clinical Pharmacology - November 13, 2018 Category: Drugs & Pharmacology Authors: Tanja Mueller, Samantha Alvarez ‐Madrazo, Chris Robertson, Olivia Wu, Marion Bennie Tags: ORIGINAL ARTICLE Source Type: research

Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants.
ConclusionsThere is a twofold increase of the risk for AMI for DOACs, in comparison with VKAs in AF therapy. In addition results suggest that in patients with AF, during aspirin monotherapy, incidence of AMI is higher than during the use of VKAs.
Source: British Journal of Clinical Pharmacology - March 23, 2017 Category: Drugs & Pharmacology Authors: Leo M. Stolk, Frank Vries, Chiel Ebbelaar, Anthonius Boer, Tom Schalekamp, Patrick Souverein, Arina Cate ‐Hoek, Andrea M. Burden Tags: PHARMACOEPIDEMIOLOGY Source Type: research